Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia.

ABSTRACT:

Background

Nascent evidence-based guidelines advocate the use of Mineralocorticoid Receptor Antagonists (MRAs) in all heart failure patients with reduced ejection fraction (HFrEF) to abridge cardiovascular mortality and morbidity. This study assessed the utilization patterns and dose optimization of MRAs among patients with HFrEF at Dessie Comprehensive Specialized Hospital, Ethiopia, from March to August 2024.

Methods

A cross-sectional analysis of 260 adult patients with confirmed HFrEF, who had been under follow-up for at least six months, was conducted. MRA use and dose optimization were evaluated according to 2022 American Heart Association (AHA) guidelines. Logistic regression identified factors associated with MRA use, with statistical significance set at p < 0.

SUBMITTER: Hassen M 

PROVIDER: S-EPMC12494932 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature